Objective: To investigate the effects of increasing Cu intakes, above the usual dietary intake, on biomarkers of bone metabolism in healthy young adult females (aged 21 ± 28 y) over a 4 week period. Design: A double-blind, placebo-controlled randomised repeat crossover Cu supplementation trial. Setting: The study was conducted at the Royal Veterinary and Agricultural University (RVAU), Copenhagen, Denmark. Subjects: Sixteen healthy young adult females aged 20 ± 28 y were recruited from among students at the RVAU. Intervention: During the 4 week intervention periods in this randomised, crossover trial (3Â4 weeks with a minimum 3 week wash-out period), each subject received, in addition to their usual diet, either 3 or 6 mg elemental Cuaday as CuSO 4 or a matching placebo. On the last 3 days of each dietary period 24 h urines were collected. In addition, blood was collected on the last day of each dietary period. Results: Serum Cu and erythrocyte superoxide dismutase (but not caeruloplasmin protein concentration or activity (putative indices of Cu status)) were signi®cantly increased (P`0.05) after daily Cu supplementation with 3 and 6 mgaday for 4 weeks. Serum osteocalcin (biomarker of bone formation), urinary creatinine (Cr) concentration, urinary pyridinoline (Pyr)aCr or deoxypyridinoline (Dpyr)aCr excretion, or daily urinary Pyr or Dpyr excretion (biomarkers of bone resorption) were unaffected by Cu supplementation. Conclusion: Copper supplementation of the usual diet in healthy young adult females, while apparently improving Cu status, had no effect on biochemical markers of bone formation or bone resorption over 4 week periods. Sponsorship: Funding from the European Commission.
Introduction
Copper has an important role in the metabolism of the skeleton, where it performs a key catalytic function as a cofactor for lysyl oxidase (E.C. 1.4.3.13), a Cu-dependent extracellular amine oxidase which is important in the ®rst step of the maturation (crosslinking) of collagen to form stable ®brils (O'Dell, 1981; Tinker et al, 1988) . Studies in experimental animals have shown that Cu de®ciency can reduce greatly the activity of lysyl oxidase in bone (Siegel et al, 1970) and impair the crosslinking of collagen in the organic bone matrix (Robins et al, 1985; Farquharson et al, 1989; Jonas et al, 1993a) , leading to diminished tensile strength of bone (Jonas et al, 1993b) . In humans, there is some evidence for a role for Cu de®ciency in age-related osteoporosis. For example, Conlan et al (1990) found that serum Cu levels of 46 elderly patients with fractures of the femoral neck were signi®cantly lower than those of a group of controls matched for age and sex. A signi®cant positive correlation between serum Cu concentration and bone mineral density (BMD) at the lumbar spine has been reported in a cross-sectional study in postmenopausal women (Howard et al, 1990) .
Recently, we have shown that a low dietary Cu intake (0.7 mg per day) for 6 weeks signi®cantly increased the rate of bone resorption, as assessed by the urinary excretion of pyridinium crosslinks, in healthy adult males aged between 20 and 59 y (Baker et al, 1999a ). An increased rate of bone resorption is considered an early indicator of increased bone turnover (Eyre, 1992) and, furthermore, an increased rate of bone turnover in adults may be a risk factor for fracture (Riggs et al, 1996) , because it exacerbates bone loss (Hansen et al, 1991) . An effect of Cu on bone turnover may explain the observation of Eaton-Evans et al (1996) , who reported that Cu supplementation with an additional 3 mgaday for 2 y in middle-aged women (45 ± 56 y), led to a reduced rate of loss of BMD at the lumbar spine, suggesting that inadequate dietary Cu intake may be a contributory factor to age-related bone loss in this population group.
These ®ndings may have consequences for bone health of many adults because, while mean daily Cu intakes of adults in Europe (1.0 ± 2.26 mg for males, 0.9 ± 1.79 mg for females, Van Dokkum, 1995) are greater than or close to the EU population reference intake (PRI; 1.1 mgaday for adults; Report of the Scienti®c Committee for Food, 1993), there may be signi®cant numbers of individuals with marginal Cu intakes. For example, Klevay et al (1993) suggests that more than 30% of diets in North America and Europe provide less than 1.0 mgaday. Moreover, this effect of marginal Cu intake on bone health may be more of a concern for females than males because, in general, total Cu intake by women is less than that by men (Johnson et al, 1992 ; see review by Van Dokkum, 1995) .
Marginal Cu intake in young adult life, through its effect on bone resorption, may also limit achievement of maximal peak bone mass and thus increase risk of future fracture. There is evidence to suggest that there is potential for gain in bone mass in young adults for about 10 y after longitudinal bone growth has stopped (Recker et al, 1992; Institute of Medicine, 1997) . However, there has been no study of the effect of increasing dietary Cu intake above usual levels on bone mass or bone metabolism in this lifestage group.
The objective of the present study, therefore, was to investigate the effects of increasing Cu intakes, above the usual dietary levels, on biomarkers of bone metabolism in healthy young adult females (aged 21 ± 28 y) over a 4 week period.
Methods

Subjects
Sixteen young healthy adult females (mean age 24.2 (range 21 ± 28) y) were recruited from among students at the Royal Veterinary and Agricultural University, Copenhagen, Denmark. The mean height, weight and body mass index (BMI) for the subjects are provided in Table 1 . All subjects were healthy, without any history of bone or articular disease, and with no intake of medicine that could affect bone or cartilage metabolism. Additional exclusion criteria included smoking, chronic illness, taking nutritional supplements or oral contraceptives, pregnancy, breast-feeding, or excessive physical activity.
Ethical considerations
Before participation in this study, all subjects signed an informed consent document approved by the Local Research Ethics Committee for Copenhagen and Frederiksberg.
Experimental design
The study consisted of a double-blind, placebo-controlled randomised repeat crossover trial of the effect of Cu supplementation of the usual dietary Cu intake, using two supplementation regimens (ie 3 or 6 mg Cuaday), on biochemical markers of bone turnover in healthy young adult females.
The Cu intervention trial was designed as a randomised, crossover trial (3Â4 weeks with a minimum 3 week washout period). During the 4 week intervention periods, each subject received, in addition to their usual diet, either 3 or 6 mg elemental Cuaday, as CuSO 4 , or a matching placebo (Thomson & Joseph Ltd, Norwich, Norfolk, UK) . Subjects were requested to take the active capsule or matching placebo once daily. Subjects were provided with supplements on a weekly basis and any tablets not taken were returned by the subjects and counted.
Overall compliance of the subjects was very high (ie over 95%). Subjects were instructed to collect 24 h urines for the last 3 days of each 4 week intervention period. To ensure complete collection of urine PABA (paraaminobenzoic acid) was given on these three collection days. In addition, after an overnight fast, a blood sample (10 ml) was taken between 08:00 and 10:00 h on the morning of the last day of each 4 week dietary period.
Collection and preparation of samples
Subjects were supplied with suitable collection containers for urine samples and asked to collect 24 h urines each day Dietary Cu supplementation and bone biomarkers KD Cashman et al for the last three consecutive days of each intervention period. Portions of urine were stored at À20 C from the morning of collection until required for analysis. Blood was collected by venepuncture into vacutainer tubes containing either no additive, citrate or natrium heparin. Blood samples collected in additive-free vacutainer tubes and vacutainer tubes with natrium heparin were processed to serum and plasma, respectively, which were immediately stored at À20 C (for serum Cu and caeruloplasmin) or À80 C (for serum osteocalcin) until required for analysis. Erythrocytes were resuspended with 154 mM NaCl in the original blood volume and washed three times by centrifugation (1700 g, for 10 min at 4 C). A 500 ml aliquot of washed erythrocytes was stored at À80 C until required for determination of haemoglobin (Hb) concentration and superoxide dismutase (SOD; EC 1.15.1.1) activities.
Experimental techniques
Urinary pyridinoline and deoxypyridinoline. Each of the separate daily urine samples from each individual collected over three consecutive days was analysed in triplicate using a three-step procedure. Urine was ®rst hydrolysed with an equal volume of 12 M HCl at 110 C for 18 h, the crosslinks were then extracted by CF1 cellulose chromatography with the use of an internal standard (acetylated pyridinoline, MetraBiosystems Ltd, Wheatley, Oxon, UK) and were measured using a reversed-phase HPLC method with¯uor-escence detection (Colwell et al, 1993) . The acetylated pyridinoline was used in accordance with the method as described by Calabresi et al (1994) and Robins et al (1994) . The crosslink contents of urine samples were quantitated by external standardisation using a commercially available pyridinolineadeoxypyridinoline HPLC calibrator (MetraBiosystems Ltd). The mean content of the pyridinium crosslinks in the three separate urine collections was used to represent the individual's excretion in that dietary period. The intra-assay coef®cient of variation (CV) for pyridinoline (Pyr) and deoxypyridinoline (Dpyr), measured as the variation between 10 chromatograms obtained between column regenerations as described by Colwell et al (1993) , was 6% and 7%, respectively. Inter-assay variation was avoided by analysing all samples from an individual in the same run.
Urinary creatinine. Daily urine samples were analysed in duplicate by a colorimetric procedure using a diagnostic kit (catalogue no 124, 192; Boehringer Mannheim GmbH, Mannheim, Germany). The intra-and inter-assay CV were 3.4%, and 6.3%, respectively.
Urinary para-aminobenzoic acid. PABA in urine was measured spectrophotometrically (Perkin-Elmer LAMDA 15 UVaVIS spectrometers, U È berlingen, Germany). The inter-assay CV was 4.9%.
Serum osteocalcin. Serum osteocalcin levels were assayed in duplicate using an enzyme-linked immunosorbent assay (ELISA, BRI-Diagnostics, Dublin, Ireland). The intraassay CV was 10.2%. Inter-assay variation was avoided by analysing all samples from an individual in the same run.
Serum copper. Cu was analysed in duplicate in serum samples by atomic absorption spectrophotometry (Spectra AA-200, Varian, Victoria, Australia). The inter-assay CV was 6.9%.
Serum total caeruloplasmin and caeruloplasmin activity. Serum caeruloplasmin (Cp) protein concentration was measured turbidimetrically using a modi®cation of the method of Calvin and Price (1986) . Plasma (pH 7.3) was diluted (1:41, vav) with 0.01 M phosphate buffered saline (PBS, pH 7.3) and mixed with excess rabbit anti-human Cp (Dako, Glostrup, Denmark). The resulting antibody ± antigen complex was stabilised with a phosphate buffer containing polyethylene glycol 7000 (BDH Ltd, Poole, UK). The absorbance was measured on the Cobas Fara autoanalyser (Roche, Basel, Switzerland), and concentration was determined from a standard curve calculated using a human serum protein calibrator (Dako). The intra-assay CV was 1.7%. Interassay variation was avoided by analysing all samples from an individual in the same run. Serum Cp oxidase activity was determined by a modi®cation of the method by Henry et al (1960) , using p-phenylenediamine dihydrochloride (Sigma Aldrich Co Ltd, Poole, UK) as substrate and measuring the rate of oxidation of p-phenylenediamine dihydrochloride at 37 C. Analysis was performed on the Cobas Fara autoanalyser (Roche). The intra-assay CV was 2.2%. Inter-assay variation was avoided by analysing all samples from an individual in the same run.
Erythrocyte haemoglobin and superoxide dismutase. Determination of Hb concentration was performed using the cyanomethemoglobin method. Erythrocytes (40 ml) were diluted with 20 ml of diluent (Iston; Coulter Electronics Ltd, Bedfordshire, UK), in a plastic vial (Sterilin, BDH Ltd). The samples were mixed by inversion and six drops of a lysing solution (Zapoglobin; Coulter Electronics Ltd) were added. The samples were left for 5 min at room temperature, and the Hb concentration was determined within 1 h, in gal, using a hemoglobinometer (Coulter Electronics Ltd). Erythrocyte SOD activity was determined on the Cobas Fara automatic analyser (Roche), by a modi®cation of the method of Jones and Suttle (1981) , using a commercial kit (Ransod; Randox Laboratories, Co. Antrim, N. Ireland). Activity of SOD was expressed per g Hb. The intra-assay CV was 2.7%. Inter-assay variation was avoided by analysing all samples from an individual in the same run.
Statistical analysis
Data are presented as means with their standard deviations (s.d.). Data for all variables were normally distributed and Dietary Cu supplementation and bone biomarkers KD Cashman et al allowed for parametric tests of signi®cance. Changes in the putative indices of Cu status and in the biochemical indices of bone turnover during the 0, 3 and 6 mg Cu intervention periods were analysed by the repeated measures ANOVA, after con®rming that there were no signi®cant carry-over effects. Where a signi®cant F-value was found, the least signi®cant difference (LSD) test for multiple means was used as a post hoc test to determine which treatment means differed (Steel & Torrie, 1980) .
Results
The effects of different Cu supplementation regimens on putative indices of Cu status are shown in Table 2 . There was a signi®cant increase (P`0.05) in serum Cu concentration ($14%) in the young adult females after daily supplementation with 3 mg Cu for 4 weeks. However, supplementation with 6 mg Cuaday led to no further signi®cant increase. Similarly, there was a signi®cant increase (P`0.05) in erythrocyte SOD activity ($11%) after supplementation with 3 mg Cuaday, but supplementation with 6 mg Cuaday led to no further signi®cant increase.
Serum total Cp protein concentration and Cp activity were unaffected by either Cu supplementation regimen (ie 3 or 6 mg Cuaday). There was a tendency (P 0.079) for the ratio of Cp activity to Cp protein concentration in serum to be greater after supplementation with 3 and 6 mg Cuaday.
The effects of different Cu supplementation regimens on biochemical markers of bone turnover are shown in Table 2 . Serum osteocalcin (a marker of bone formation), urinary creatinine (Cr) concentration, urinary PyraCr or DpyraCr excretion (markers of bone resorption), daily (ie 24 h) excretion of Pyr or Dpyr in urine, or the ratio of Pyr to Dpyr in urine were unaffected by either Cu supplementation regimen.
Discussion
Under normal conditions, the concentration of Cu in serum is apparently regulated by strong homeostatic mechanisms (Milne, 1998) . Low serum Cu concentrations are nearly always the consequence of severe Cu de®ciency, and are almost always indicative of depleted Cu stores (Milne et al, 1990) . However, in instances of marginal Cu de®ciency or in short-term studies of experimental Cu deprivation, circulating Cu responses have been variable (Milne, 1998) . The signi®cant increase in serum Cu levels of the young adult females in the present study, when supplemented with 3 and 6 mg Cuaday compared to placebo, could indicate that their habitual intake of Cu was inadequate and that the females had depleted Cu stores. Several studies of apparently healthy adults have reported a lack of response of circulating Cu to daily supplementation of the usual diets with additional Cu (in the range 2 ± 10 mgaday; Pratt et al, 1985; Medeiros et al, 1991; Eaton-Evans et al, 1996; Milne & Nielsen, 1996; Kehoe et al, 2000) . However, serum Cu is generally considered an unreliable index of Cu status (Strain, 1998) .
Circulating Cp concentration and erythrocyte SOD activity have been proposed as being more re¯ective of metabolically active Cu and Cu stores than is plasma Cu concentration (Milne, 1994 (Milne, , 1998 . In the present study, there was no effect of Cu supplementation with either 3 or Mean values within a row with different superscript letters were signi®cantly different, P`0.05, using least signi®cant difference test for post hoc analysis. b Representing the ratio of Pyr to Dpyr in urine, both of which were expressed on a creatinine basis. c Representing Pyr and Dpyr excretion over a 24 h period.
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KD Cashman et al 6 mg elemental Cuaday for 4 weeks on serum Cp concentration or Cp enzyme activity in young adult females. This is in agreement with the ®ndings of several studies which have shown a lack of response of circulating Cp protein levels to daily supplementation with 2 ± 6 mg Cu (Medeiros et al, 1991; Eaton-Evans et al, 1996; Baker et al, 1999b) . However, it has been suggested that the speci®c enzymatic activity of Cp, de®ned as the ratio of enzyme activity to the immunoreactive protein, is a better indicator of Cu status than either the enzymatic activity or immunoreactive protein alone (Milne et al, 1988; Milne, 1994) . Interestingly, while failing to reach signi®cance (P 0.079) in the present study, there was a tendency towards a greater ratio of Cp activity to Cp protein with Cu supplementation compared to placebo. The increase in erythrocyte SOD activity in the present study after daily supplementation of the usual diet with 3 or 6 mg Cu for 4 weeks may indicate that the Cu status in the subjects was improved by supplementation. This is in contrast with the ®ndings of other Cu intervention studies, which showed that supplementation of the usual diet with additional Cu (in the range 3 ± 6 mgaday) had no effect on erythrocyte SOD (Medeiros et al, 1991; Eaton-Evans et al, 1996; Baker et al, 1999b) . For example, we have recently shown in another double-blind, placebo-controlled crossover trial that Cu supplementation with 3 or 6 mg elemental Cuaday for 6 weeks had no effect on erythrocyte SOD or serum Cp protein concentration in healthy adults (12 males and 12 females, aged 22 ± 46 y; Baker et al, 1999b) . On the other hand, in depletion ± repletion type studies of women, in which SOD activity declined during Cu deprivation, recoveries of SOD activity were documented when either 3 mg (Reiser et al, 1985) or 4.3 ± 6.4 mg Cuaday were fed for more than 30 days (Kelvay et al, 1984; Miline et al, 1990) , but not when less than 2.6 mg Cuaday was fed for periods of up to 42 day (Milne et al, 1988; Milne & Nielsen, 1996) . This is consistent with the ®ndings of the present study, which showed that SOD activity increased after supplementation with 3 and 6 mg Cuaday for 28 days.
Together, these data may indicate that the habitual intake of Cu in these subjects was inadequate and that the females had depleted Cu stores. Unfortunately, habitual dietary Cu intakes were not estimated in the present study, because of the intractable problems in calculating measures of Cu intake. For example, calculations of Cu content in intervention diets used by us in the past based on the Danish Nutrition Data Base gives Cu concentrations of 1.1 mga10 MJ, whereas measurements by atomic absorption spectroscopy gives 0.86 mg Cua10 MJ (unpublished data). Nonetheless, non-published data from The National Danish Survey performed in 1985 indicate that the average dietary Cu intake for women aged 15 ± 80 y was 1.1 mgaday based on calculations using the Danish Nutrition Data Base (oral communication to SB), but this is likely to be an overestimate.
Marginal Cu intakes may have serious implications for bone health. For example, we have recently shown that a low dietary Cu intake (0.7 mgaday) for 6 weeks signi®-cantly increased the rate of bone resorption, as assessed by the urinary excretion of pyridinium crosslinks (sensitive and speci®c biochemical markers of bone resorption; Eyre, 1992; Robins & New, 1997) , in healthy adult males aged between 20 and 59 y (Baker et al, 1999a ). An increased rate of bone resorption is considered an early indicator of increased bone turnover (Eyre, 1992) and furthermore, an increased rate of bone turnover in adults may be a risk factor for fracture (Riggs et al, 1996) , because it exacerbates bone loss (Hansen et al, 1991) . High rates of bone turnover are also associated with a disruption of the trabecular network leading to a loss of connectivity which is not necessarily re¯ected in a decrease in bone mass (Par®tt, 1984) . Importantly, in that study, the increased urinary pyridinium crosslinks excretion observed in healthy adult males at the end of a 6 week period of Cu depletion (0.7 mg Cuaday), was reversed during a subsequent 6 week period of dietary Cu repletion (ie 6.0 mg Cuaday; Baker et al, 1999a) , suggesting that the elevated rate of bone resorption was quickly normalised by increasing Cu intake.
While the underlying mechanisms for the osteoporoticlike lesions observed in bone in Cu de®ciency disorders in animal species and humans are not understood, such abnormalities are generally considered to be owing to defective bone formation secondary to reduced lysyl oxidase activity (Danks, 1988) . However, reduced lysyl oxidase activity with consequent reduction in collagen crosslinking does not readily explain the increased excretion of pyridinium crosslinks observed during the depletion period in our previous study (Baker et al, 1999a) . Similarly, an increased lysyl oxidase activity with consequent increase in collagen crosslinking does not readily explain the decreased excretion of pyridinium crosslinks during the repletion period in our previous study (Baker et al, 1999a) . It may be that changes in dietary Cu intake may have in¯uenced osteoclastic bone resorption, as a consequence of faulty collagen crosslinking or by some other mechanism, eg direct effect on bone cell activity. It has been suggested that decreased activity of other Cu-dependent enzymes may also be involved in bone alterations as a consequence of Cu-de®ciency (Strain, 1998) . For example, superoxide dismutase, which dismutates the superoxide radical, is one such Cu-dependent enzyme. Osteoclasts are known to produce superoxide and decreased activities of this enzyme could conceivably lead to increased bone resorption (Rico, 1991 ). An increased rate of bone resorption has been suggested as one explanation for the reduced bone mass observed in Cu-de®cient rats (Strause et al, 1986) . Furthermore, studies carried out in vitro have shown that Cu reduces active bone resorption, as measured by release of 45 Ca or hydroxyproline into the bathing medium from cultured explanted 45 Ca-labelled mouse calvaria bone grown in medium with or without the addition of Cu over a 48 h period (Wilson et al, 1981; Katz et al, 1984) . The concentration of Cu used in media in these in vitro studies corresponded to physiological concentrations of Cu found Dietary Cu supplementation and bone biomarkers KD Cashman et al in experimental mice. Wilson et al (1981) suggested, based on their in vitro data, that a higher Cu concentration, but within the physiological range, reduces bone resorption.
The ®ndings of the present study showed that, despite increases in putative indices of Cu status, oral Cu supplementation with either 3 or 6 mg elemental Cuaday for 4 weeks had no effect on urinary pyridinium crosslinks of collagen (Pyr and Dpyr) or serum osteocalcin (a sensitive biochemical marker of bone formation; Eyre, 1996) in healthy young adult females. These ®ndings agree well with our recent ®ndings from a similar Cu intervention trial which showed that supplementation of the usual diet with either 3 or 6 mg elemental Cuaday for 6 weeks had no effect on urinary pyridinium crosslinks of collagen (Pyr and Dpyr) or serum osteocalcin in healthy adults (males and females, aged 22 ± 46 y; Baker et al, 1999b) . However, in that study, unlike the present study, putative indices of Cu status were unaffected by Cu supplementation, suggesting that the habitual dietary Cu intake (mean intakes of 1.4 and 1.1 mg Cuaday for males and females, respectively) of these adults was adequate.
The ®ndings from our present and previous studies (Baker et al, 1999a,b) , when taken together, suggest that there may be a threshold effect of dietary Cu on bone metabolism, whereby dietary Cu intakes above about 1 mgaday (a value similar to the recommended intake) are of no apparent bene®t to bone metabolism in healthy adult males or premenopausal females. However, EatonEvans et al (1996) reported that Cu supplementation of the usual diet with 3 mgaday for 2 y reduced the rate of loss of BMD at the lumbar spine in the 45 to 56-y-old women whose usual dietary Cu intake was about 1 mgaday. There are several possible reasons why additional dietary Cu positively in¯uenced bone mass in the study of EatonEvans et al (1996) . For example, as over half the females in the study were either perimenopausal or postmenopausal and, therefore, likely to have lower oestrogen status, this may have in¯uenced the effect of Cu on bone. On the other hand, as the study was 2 y in duration it might be possible that bone collagen would be more cross-linked, as a consequence of the higher Cu intake, and possibly more resistant to osteoclastic resorption. Alternatively, it may be that increasing dietary Cu intakes above the usual level does suppress the rate of bone resorption as a consequence of reduced osteoclastic activity, but that it may take up to 2 y before differences are apparent in BMD.
Conclusion
Cu supplementation of the usual diet in healthy young adult females while apparently improving Cu status, had no effect on biochemical markers of bone formation or bone resorption over 4 week periods. However, more research is needed to examine the effects of increased Cu intake on bone metabolism and bone mass in older adults, particularly peri-and post-menopausal females, and especially in long-term studies.
